tbuckley/cabot-search huggingface dataset:
HYDROTHERAPY IN OSTEOARTHRITIS
Authors: J D CURRENCE
Journal: Annals of Internal Medicine (1950)

Article1 April 1950HYDROTHERAPY IN OSTEOARTHRITISJOHN D. CURRENCE, M.D., F.A.C.P.JOHN D. CURRENCE, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-4-682 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe use of hydrotherapy is one of the oldest therapeutic measures in our medical armamentarium. From ancient Greek, Roman and Hindu writings, we find that balneology was highly developed, probably reaching its peak in the declining centuries of the Roman Empire. There is no record, however, that the specific therapeutic indications for the baths were known at that time.1As a result of the many clinical investigations into the etiology and pathogenesis of osteoarthritis, we may conclude that the disease is a degenerative one, hence the terms hypertrophic or degenerative arthritis. For the most part it is a senescent process,...Bibliography1. Currence JD: An improved method of underwater treatment of arthritis, Arch. Phys. Therapy 19: 84, 1938. Google Scholar2. HadenWarren RLWA: Accelerating factors in hypertrophic osteoarthritis, Jr. Lab. and Clin. Med. 21: 448, 1936. Google Scholar3. CecilBarrDuBois RLDDEF: Clinical calorimetry, observations on metabolism of arthritis, Arch. Int. Med. 20: 583, 1922. CrossrefGoogle Scholar4. Kovacs R: Yearbook of physical medicine of 1946, Yearbook Publishers, Inc., Chicago, Ill. Google Scholar5. Currence JD: Recent hydrotherapeutic observations in arthritis, Arch. Phys. Therapy 15: 490, 1934. Google Scholar6. CecilArcher RLBH: Arthritis in the menopause, J. A. M. A. 84: 75, 1925. CrossrefGoogle Scholar7. Hoggart GE: Degenerative arthritis of the hip joint, J. A. M. A. 78: 502, 1945. CrossrefGoogle Scholar8. Livingston WK: Pain mechanisms, 1942, Macmillan Co., New York. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication September 28, 1948. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRHEUMATISM AND ARTHRITIS REVIEW OF AMERICAN AND ENGLISH LITERATURE OF RECENT YEARS (TENTH RHEUMATISM REVIEW)* Part IIWILLIAM D. ROBINSON, M.D., F.A.C.P., EDWARD W. BOLAND, M.D., F.A.C.P., JOSEPH J. BUNIM, M.D., F.A.C.P., DARRELL C. CRAIN, M.D., F.A.C.P., EPHRAIM P. ENGLEMAN, M.D., F.A.C.P., WALLACE GRAHAM, M.D., F.R.C.P. (C), L. MAXWELL LOCKIE, M.D., F.A.C.P., MAX M. MONTGOMERY, M.D., F.A.C.P., CHARLES RAGAN, M.D., F.A.C.P., MARIAN W. ROPES, M.D., F.A.C.P., EDWARD F. ROSENBERG, M.D., F.A.C.P., CHARLEY J. SMYTH, M.D. 1 April 1950Volume 32, Issue 4Page: 682-687KeywordsEtiologyOsteoarthritisPathogenesis ePublished: 1 December 2008 Issue Published: 1 April 1950 PDF downloadLoading ...
The gene mutated in bare patches and striated mice encodes a novel 3β-hydroxysteroid dehydrogenase
Authors: Xiao Yu Liu, Andrew W. Dangel, Richard I. Kelley, Wei Zhao, Paul Denny, Marc Botcherby, Bruce Cattanach, Jo Peters, Patricia R. Hunsicker, Ann-Marie Mallon, Mark A. Strivens, Rachael Bate, Webb Miller, Michael Rhodes, Stephen D.M. Brown, Gail E. Herman
Journal: Nature Genetics (1999)
Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients
Authors: M. Kasperkiewicz, I. Shimanovich, M. Meier, N. Schumacher, L. Westermann, J. Kramer, D. Zillikens, E. Schmidt
Journal: British Journal of Dermatology (2011)

Background It has been previously shown in a relatively small group of patients that a combination of immunoadsorption (IA) and rituximab with daily use of high‐dose oral corticosteroids and azathioprine/mycophenolate mofetil may induce a rapid and durable remission in severe, treatment‐resistant pemphigus. Objectives To achieve a more rapid reduction of serum autoantibody levels by a more frequent use of IA in the initial phase of treatment and to reduce the number of severe adverse events of continuous oral corticosteroid therapy by switching to pulsed intravenous applications. Methods Twenty‐three consecutive patients with severe pemphigus were included. IA was performed at initially 3‐ and later 4‐week intervals until lesions healed by 90%; 1000 mg rituximab was given at weeks 1 and 3, and intravenous dexamethasone pulses were administered at first every 3 weeks and then at increasing intervals in addition to daily azathioprine/mycophenolate mofetil. Results Along with a fast and durable decline of circulating autoantibody levels, all patients showed improvement of pemphigus lesions within the first weeks of therapy and long‐term complete remission was induced in 19 (83%) patients. In the remaining four patients, one (4%) minimal disease and three (13%) partial remissions were observed. Over the long‐term follow‐up of 11–43 (mean 29) months, six (26%) patients had a recurrence and in two (9%) patients, severe adverse events occurred. Conclusions This novel protocol treatment induces a fast and long‐term remission in severe pemphigus and seems to offer an improved side‐effect profile compared with daily use of corticosteroids.
Tick-borne encephalitis (TBE) virus prevalence and virus genome characterization in field-collected ticks (Ixodes ricinus) from risk, non-risk and former risk areas of TBE, and in ticks removed from humans in Germany
Authors: C. Klaus, B. Hoffmann, U. Hering, B. Mielke, K. Sachse, M. Beer, J. Süss
Journal: Clinical Microbiology and Infection (2009)
564. T Cell Immunity Using Transgenic B Lymphocytes
Authors: Mara Gerloni, Marta Rizzi, Paola Castiglioni, Maurizio Zanetti
Journal: Molecular Therapy (2004)

Top of pageAbstract
T cell responses begin when precursor T cells recognize antigen on specialized antigen-presenting cells (APCs) and differentiate into effector cells. Here we present evidence that primary naive B lymphocytes can be genetically-programmed using non-viral DNA and turned into powerful APCs with a dual capacity of synthesis and presentation of antigen to T cells in vivo. We found that a single intravenous injection of transgenic B lymphocytes in naive immunocompetent mice activates T cell responses reproducibly and specifically even at very low cell doses (102). Interestingly, these T cell responses can occur in the absence of dendritic cells and result in immunological memory with protective effector functions. Using plasmid DNA coding for the dominant epitope (NP366-374) of the influenza virus nucleoprotein, we were able to study the characteristics of the CD8 T cell memory response in C57Bl/6 mice and its relation to protection. We found that memory CTL responses are protective at very low dose (3102 cells/inoculum), and that protection in particular is mediated by CD8 T cells of the central memory type. These findings disclose new directions in the use of plasmid DNA for interventions aimed at producing immunological effects in vivo. Key aspects of the new working principles are the direct involvement of antigen presenting cells (transgenic B lymphocytes) in an in vivo process characterized by (1) a capacity of the injected lymphocytes to home to secondary lymphoid organs, (2) a protracted self-renewing capacity of antigen synthesis processing and presentation directly at the site of immune induction (the secondary lymphoid organs), and (3) the potential for mobilizing a generalized immune response. These characteristics together with the fact that the generation of immunity by transgenic B lymphocytes occurs within the spatio-temporal geometry of organized secondary lymphoid organs, enable this new approach with a spectrum of potential applications for vaccination against viruses and cancer in humans.
A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis
Authors: None Jahangir, None Hussain, None UL Hasan, None Haroon
Journal: British Journal of Dermatology (1998)

In this randomized, double-blind study, the efficacy and safety of oral itraconazole (n = 28) and terbinafine (n = 27), each given for 2 weeks, was compared in patients with tinea capitis. Trichophyton violaceum was the major pathogen in both groups (82.1% and 88.9%, respectively). The final evaluation at week 12 showed a cure rate of 85.7% and 77.8%, respectively (P > 0.05). Adverse events noted were mild and did not warrant discontinuation of therapy.
Abstract P2-12-15: Perception of women after undergoing microbiopsy following a positive breast cander screening
Authors: Birgit Carly, Mireille Aimont, Nicolas Beauloye, Fabienne Liebens
Journal: Cancer Research (2015)

Abstract Background: Some authors have challenged the benefit of breast cancer mammographic screening due to high prevalence of overdiagnosis and overtreatment. Purpose: To assess the anxiety and stress of women undergoing a microbiopsy following a false positive breast cancer screening and to evaluate whether this experience refrains them from continuing breast cancer screening. Methods: 296 patients underwent breast microbiopsy for positive breast cancer screening B1, B2 and B3 lesions in our Breast Center between 2011 and 2013. Patients undergoing microbiopsy for B4 and B5 lesions were excluded from the study. The patients were thereafter interviewed by our two psychologists by phone within a time range of 6 to 18 months following the biopsy. Results: 201 women answered the questionnaire (68% response). 5.5% had a breast lesion at risk and 75% had a benign lesion. Half of the women rated their anxiety as high (7-8 on a scalebetween 0 – 10) and 15% as very high (9-10/10) before the biopsy. While waiting for the result, 42% rated their anxiety as high (7-8/10) and nearly a third as very high (9-10/10). But 80% accepted to continue breast cancer screening and 90% would accept to undergo again a microbiopsy if necessary. Conclusion: microbiopsy provides high stress in most patients undergoing it. Nevertheless, 90% of those who had a false positive results accept it and are willing to undergo a biopsy again if necessary. Citation Format: Birgit Carly, Mireille Aimont, Nicolas Beauloye, Fabienne Liebens. Perception of women after undergoing microbiopsy following a positive breast cander screening [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-12-15.
Press: Clouding the AIDS issue
Authors: P. Sidley
Journal: BMJ (2000)

South Africa's president, Thabo Mbeki, is once again at the centre of a medical and scientific storm over the issue of HIV and AIDS, attracting a great deal of criticism from the media. The last time it occurred it was over the announcement of a “miracle cure” for AIDS, which turned out to have no medical value whatever and proved to cause only harm to patients illegally receiving the drug. The inventors of the cure, Virodene, bypassed all the research protocols and controls at universities and went directly to the thenminister of health, Nkosazana Dlamini-Zuma. Dr Zuma presented the pair and their claims to a cabinet meeting, and they were hailed for their “discovery.”

In the debacle that followed, Mbeki, then the deputy president, was thoroughly convinced by the “researchers.” He was so taken by their case that when a financial squabble broke out among the “research team” he personally intervened, arranging early morning secret meetings with Zuma to organise a peace meeting between the warring parties. The …
The American Hospital of the Twentieth Century. A Treatise on the Development of Medical Institutions, Both in Europe and in America, Since the Beginning of the Present Century.
Authors: Edward Fletcher Stevens
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Suppression of Ovarian Cancer Cell Tumorigenicity and Evasion of Cisplatin Resistance Using a Truncated Epidermal Growth Factor Receptor in a Rat Model
Authors: John K. Chan, Huyen Pham, Xue Juan You, Noelle G. Cloven, Robert A. Burger, G. Scott Rose, Kristi Van Nostrand, Murray Korc, Philip J. DiSaia, Hung Fan
Journal: Cancer Research (2005)

Abstract The overexpression of the epidermal growth factor receptor (EGFR) is associated with a poor prognosis in ovarian cancer. The dominant-negative EGFR (EGFR-DNR) is a truncated receptor that lacks the tyrosine kinase domain and is devoid of signaling capability. This study tested the effects of a EGFR-DNR approach in ovarian cancer cells. NuTu-19, a rat ovarian cancer cell line was rendered resistant to cisplatin. Both NuTu-19 and resistant cells were infected with a retroviral vector containing the EGFR-DNR. NuTu-19 and NuTu-DNR (NuTu-19 cells expressing the EGFR-DNR) were injected into Fisher 344 immunocompetent rats. Western blot analyses were used to assess signal transduction pathways. All rats injected with NuTu-DNR cells remained healthy following tumor injection. In contrast, 100% of the rats injected with the NuTu-19 and NuTu-Sham (NuTu-19 cells expressing an empty vector) died of disease progression at the end of 15 weeks (P = 0.00009). On Western blot analysis, both NuTu-19 and NuTu-Sham cells showed a strong activation of mitogen-activated protein kinase (MAPK) after exposure to EGF. Cisplatin-resistant cell lines showed an enhanced EGF stimulatory effect via the MAPK pathway compared with parental cells. The EGFR-DNR significantly reduced the ability of EGF to induce cell signaling through the MAPK pathway. Lastly, the EGFR-DNR can partially reverse cisplatin resistance in drug-resistant cells. The EGFR-DNR approach suggests that EGFR confers a growth advantage to NuTu-19 cells in vivo. Thus, EGFR blockade may ultimately prove to be a useful therapeutic tool in the treatment of cisplatin-sensitive and cisplatin-resistant ovarian cancers.
Some Observations on Apn a Neonatorum
Authors: G. Greaves
Journal: BMJ (1862)

tended, I wast able, before cutting the cord, to count the SOME, OBSERVATIONS ON APN(EA ptulsations of its arteries.I founil thient to be rathier leess NE,ONATORUM.than four in five seconds, or ab)out.foirty in the miniiute, By GnnGxREAVE, Es., Leture on Mdwifry, nd yet the chiild, whichi was born al-mostinstatitaineously Manch.OR EsterRoAyalEtq.Lchlrof oned%icine fey alfter its liberation from thec restraininig rnoose ot cord, Maihse oand Sureliolof.1-dre iied lustilv before its lower limbs e!saped fr-om the rConiinziedfront pngelvagina, and gave every othier sign of vigotvus lire.
Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation
Authors: Kwok-Kin Wong, Sandy Chang, Sarah R. Weiler, Shridar Ganesan, Jayanta Chaudhuri, Chengming Zhu, Steven E. Artandi, Karl Lenhard Rudolph, Geoffrey J. Gottlieb, Lynda Chin, Frederick W. Alt, Ronald A. DePinho
Journal: Nature Genetics (2000)
Fractional exhaled nitric oxide in healthy Thai adults and its association with pulmonary function
Authors: Wilaiwan Khrisanapant, Nattha Muengritdeche, Orapin Pasurivong, Watchara Boonsawat, Boonsong Patjanasoontorn, Burabha Pussadhamma, Wannapa Ishida
Journal: European Respiratory Journal (2014)

The fractional exhaled nitric oxide (FeNO) has been proposed to be a non-invasive marker of airway inflammation. There are no studies on normal FeNO values and its link to pulmonary function among Thais. This study determined the reference values of FeNO and its association with pulmonary function among healthy non-atopic, non-regular alcoholic and non-smoking Thai adults between 20 to 50 years of age. FeNO was measured using Quark NObreath in accordance with the American Thoracic Society guidelines and pulmonary function tests were performed in 18 males and 31 females. The mean FeNO level was 12.4 ± 6.2 ppb and the upper 95% confidence limit was 14.2 ppb in 49 healthy Thai adults (33.6 ± 9.36 yrs). Moreover, it was 13.4 ± 6.5 and 11.9 ± 6.1 ppb in male and female, respectively. Males had comparable FeNO levels, FVC (%pred), FEV 1  (%pred), FEF25-75% (%pred) and PEF (%pred) to females. Moreover, there was a negative correlation between FEF25-75% with FeNO level (r =-0.298, p=0.040) but not FVC or FEV1 or PEF. The present study provides normal FeNO values in Thai adults. They were similar to those of Caucasians and Japanese. Furthermore, the FeNO level was negatively linked to FEF25-75% indicating a small airway inflammation may be present in those with higher FeNO levels. Nevertheless, large random sample of Thais are required before integrating into clinical practice.
Elevated expression levels of testis-specific genes<i>TEX101</i>and<i>SPATA19</i>in basal cell carcinoma and their correlation with clinical and pathological features
Authors: S. Ghafouri-Fard, A. Abbasi, H. Moslehi, N. Faramarzi, S. Taba taba Vakili, M.B. Mobasheri, M.H. Modarressi
Journal: British Journal of Dermatology (2009)

Journal Article Elevated expression levels of testis‐specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features Get access S. Ghafouri‐Fard, S. Ghafouri‐Fard Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Search for other works by this author on: Oxford Academic Google Scholar A. Abbasi, A. Abbasi Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Search for other works by this author on: Oxford Academic Google Scholar H. Moslehi, H. Moslehi Department of Dermatology, Razi Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Search for other works by this author on: Oxford Academic Google Scholar N. Faramarzi, N. Faramarzi Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Search for other works by this author on: Oxford Academic Google Scholar S. Taba taba Vakili, S. Taba taba Vakili Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Search for other works by this author on: Oxford Academic Google Scholar M.B. Mobasheri, M.B. Mobasheri Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Maryam Beigom Mobasheri. E‐mail:mobashed@sina.tums.ac.ir Search for other works by this author on: Oxford Academic Google Scholar M.H. Modarressi M.H. Modarressi Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 162, Issue 4, 1 April 2010, Pages 772–779, https://doi.org/10.1111/j.1365-2133.2009.09568.x Published: 01 April 2010
The Private Life of the Brain
Authors: Barbara Godlee
Journal: BMJ (2001)

Susan A Greenfield 

Penguin, £18.99, pp 258

ISBN 0 713 99192 5

Rating: ![Graphic][1]  ![Graphic][2]  ![Graphic][3]  ![Graphic][4] 

The nature and seat of consciousness—the faculty that, above all, distinguishes humans from other animals—is at the forefront of brain research, attracting scientists of every persuasion, from geneticists to psychologists. Susan Greenfield, the internationally renowned director of the Royal Institution of Great Britain, is rightly acclaimed for the many years she has spent successfully chipping away at the coal-face of brain research. One of her most valuable achievements has …

 [1]: /embed/inline-graphic-1.gif
 [2]: /embed/inline-graphic-2.gif
 [3]: /embed/inline-graphic-3.gif
 [4]: /embed/inline-graphic-4.gif
The Anergy Induction of M3 Muscarinic Acetylcholine Receptor–Reactive CD4+ T Cells Suppresses Experimental Sialadenitis‐like Sjögren's Syndrome
Authors: Hiromitsu Asashima, Hiroto Tsuboi, Hiroyuki Takahashi, Tomoya Hirota, Mana Iizuka, Yuya Kondo, Minoru Matsui, Isao Matsumoto, Takayuki Sumida
Journal: Arthritis & Rheumatology (2015)

Objective Autoreactive CD4+ T cells are involved in the pathogenesis of Sjögren's syndrome (SS). The aim of the present study was to clarify the dominant T cell epitopes of M3 muscarinic acetylcholine receptor (M3R) and to establish a new antigen‐specific therapy for SS using an experimental mouse model. Methods Production of cytokines from M3R‐reactive CD4+ T cells, after culture with various M3R peptides, was analyzed by enzyme‐linked immunosorbent assay. Adoptive cell transfer was performed using splenocytes from M3R −/− mice that were immunized with M3R peptides or phosphate buffered saline plus H37Ra as a control. Rag1 −/− mice were inoculated with the splenocytes and examined for the development of sialadenitis. Altered peptide ligands (APLs) of the T cell epitopes, with substitutions in amino acid residues at T cell receptor contact sites, were synthesized, and the ability of the APLs to suppress sialadenitis was evaluated. The mechanisms underlying such effects were assessed. Results CD4+ M3R‐reactive T cells produced interleukin‐17 (IL‐17) and interferon‐γ (IFNγ) in response to the N‐terminal 1 (N1) and 1st extracellular loop peptides of M3R, and Rag1 −/− mice that received N1‐ and/or 1st peptide–immunized splenocytes developed sialadenitis. Among the designed APLs, N1‐APL7 (N→S at amino acid 15) significantly suppressed IFNγ production in vitro, and also suppressed sialadenitis in vivo. Levels of early growth response 2 in CD4+ T cells from the cervical lymph nodes of N1‐APL7–treated mice were significantly higher than those of control mice, and cell proliferation was reversed by administration of exogenous IL‐2. Levels of the anergy‐related molecules itchy homolog E3 ubiquitin‐protein ligase, Casitas B‐lineage lymphoma b, gene related to anergy in lymphocytes, and Deltex‐1 were significantly higher in CD4+ T cells cultured with N1‐APL7. Conclusion The major T cell epitopes were from the N1 and 1st peptide regions. Moreover, N1‐APL7, selected as the antagonistic APL in vitro, also suppressed sialadenitis through the induction of anergy. This is a potentially useful strategy for regulating pathogenic T cell infiltration in SS.